熱門資訊> 正文
Plus Therapeutics获准180天恢复与纳斯达克合规
2025-11-17 21:06
- Plus Therapeutics (PSTV) announced on Monday that it has received an additional 180-day extension period from the Nasdaq to regain compliance with the $1.00 minimum bid price requirement as per Nasdaq Listing Rule 5550(a)(2).
- The company has until May 11, 2026, to meet the minimum bid price requirement.
- If at any time during the additional 180-day extension, the closing bid price of the common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Nasdaq will provide the company with a written confirmation of compliance.
More on Plus Therapeutics
- Plus Therapeutics rises on the back of UnitedHealthcare coverage deal
- Plus Therapeutics receives $1.9M CPRIT payment for cancer program
- Seeking Alpha’s Quant Rating on Plus Therapeutics
- Historical earnings data for Plus Therapeutics
- Financial information for Plus Therapeutics
推薦文章
一周財經日曆 | 迟來40天！美國9月PPI下周公佈；阿里、美團、蔚來等財報壓軸登場
港股周報 | 美聯儲「放鴿」提振市場！港股反攻，恆指期貨漲1.2%；小鵬汽車周內暴跌20%，Q4收入指引不及預期
一周IPO | 超購2769倍！量化派火熱招股中；創新實業下周一上市；遇見小面通過聆訊
美股機會日報 | 降息有戲？美聯儲「三把手」威廉姆斯稱仍有降息空間；木頭姐加倉英偉達
財報前瞻 | 股價連續調整！阿里能否交出超預期財報提振信心？AI和雲或將扛起增長大旗
港股異動 | 聯想集團午后一度漲1%，業績超預期，中金、高盛等看好其供應鏈議價能力
「木頭姐」旗艦基金自8月份以來首次買入英偉達股票
從折價到高光：港股科技板塊，AI時代的中國資產「黃金坑」
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
